Welcome to our dedicated page for Ani Pharmaceutic news (Ticker: ANIP), a resource for investors and traders seeking the latest updates and insights on Ani Pharmaceutic stock.
ANI Pharmaceuticals, Inc. reports developments as a diversified biopharmaceutical company that develops, manufactures, and commercializes therapeutics through Rare Disease, Generics, and Brands businesses. Its Rare Disease portfolio includes Purified Cortrophin® Gel and ophthalmology products such as ILUVIEN® and YUTIQ®, while its generics portfolio includes products launched through FDA-approved abbreviated new drug applications.
ANI news commonly covers quarterly and annual financial results, guidance updates, product revenue trends, FDA approvals, generic product launches, clinical data publications, investor presentations, and capital allocation actions. Company updates also describe activity in ophthalmology, rheumatology, nephrology, neurology, and pulmonology, along with manufacturing and commercialization execution in the United States.
ANI Pharmaceuticals (Nasdaq: ANIP) has announced its participation in two major healthcare conferences this November. Nikhil Lalwani, President and CEO, and Stephen Carey, CFO, will present at the Guggenheim Inaugural Healthcare Innovation Conference on November 13, 2024, at 10:00am ET, and the Jefferies London Healthcare Conference on November 20, 2024, at 2:30pm GMT/9:30am ET.
Live and archived webcasts will be available on ANI's website under the Investors section, with replays accessible for 90 days.
ANI Pharmaceuticals (NASDAQ: ANIP) has scheduled its third quarter 2024 financial results announcement for November 8, 2024, before market open. The company will host a conference call at 8:00 a.m. ET featuring CEO Nikhil Lalwani, CFO Stephen P. Carey, and Head of Rare Disease Chris Mutz. Investors can access the call toll-free at 800-445-7795 using Conference ID 4757982. A webcast will be available on the company's website under the Investors section, with a replay accessible for two weeks by calling 800-839-8389.
ANI Pharmaceuticals has received FDA approval for its Abbreviated New Drug Application (ANDA) and launched Estradiol Gel, 0.06%, a generic version of EstroGel® Gel, 0.06%. The product enters a market with annual sales of approximately $16.7 million, according to August 2024 IQVIA data. This launch represents another -competition product in ANI's portfolio, aimed at ensuring accessibility for patients and customers.
ANI Pharmaceuticals (ANIP) announced its upcoming presentation of new pre-clinical data on membranous nephropathy (MN) research at the American Society of Nephrology Kidney Week 2024 in San Diego, October 23-27. The company will showcase two poster presentations focusing on THSD7A-associated membranous nephropathy and melanocortin therapy's protective effects.
Chief Medical Officer Dr. Mary Pao highlighted the significance of their research in understanding melanocortin receptors' role in nephrotic syndrome. The presentations will be delivered by lead author Jing Liu, with sessions scheduled for October 25 and 26.
ANI Pharmaceuticals has announced the FDA approval and launch of Ketoconazole Shampoo, 2%, a generic version of Nizoral®. This approval marks another competition product for ANI, aligning with their strategic priority to launch new products addressing patient needs. The company's R&D team has been credited for this achievement.
Nikhil Lalwani, President and CEO of ANI, expressed pride in the approval and commercialization of the product. According to IQVIA data from July 2024, the U.S. annual sales for Ketoconazole Shampoo, 2% total approximately $69.2 million. This launch represents ANI's entry into a significant market segment, potentially boosting the company's revenue and market position in the pharmaceutical industry.
ANI Pharmaceuticals (ANIP) has completed its acquisition of Alimera Sciences, strengthening its Rare Disease segment. The deal adds approximately $105 million in 2024 revenue on a pro forma basis and expands ANI's footprint to 20 countries. Key points include:
1. Addition of two commercial assets: ILUVIEN® and YUTIQ® with growth potential in ophthalmology
2. Expected to drive high single-digit to low double-digit accretion in adjusted non-GAAP EPS in 2025
3. New capital structure reducing interest expense by approximately $39 million annually
4. Expansion of Rare Disease segment to ~45% of pro forma 2024 revenues
5. Potential for accelerated growth of Cortrophin Gel in ophthalmology
ANI maintains its 2024 financial guidance for the standalone company based on continued momentum across Purified Cortrophin® Gel and Generics.
ANI Pharmaceuticals (Nasdaq: ANIP) has initiated closing logistics for its previously announced acquisition of Alimera Sciences (Nasdaq: ALIM). The company expects to complete and announce the closing of the acquisition today, September 16, 2024, subject to the satisfaction or waiver of any remaining customary closing conditions. This strategic move signifies a significant expansion for ANI Pharmaceuticals, potentially enhancing its market position and product portfolio. The acquisition of Alimera Sciences, a company known for its focus on retinal diseases, could bring new opportunities and synergies to ANI's existing pharmaceutical operations.
ANI Pharmaceuticals (Nasdaq: ANIP) has launched Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution, 6.25 mg/15 mg per 5 mL. This marks the company's 14th new product launch in 2024, contributing to strong growth in its Generics business. The timing of the launch is strategic, coinciding with the upcoming cough and cold season.
According to IQVIA data from July 2024, the U.S. annual sales for this oral solution total approximately $42.6 million. This launch aligns with ANI's strategy to expand its product portfolio and capitalize on market opportunities in the pharmaceutical sector.
ANI Pharmaceuticals (NASDAQ: ANIP) and Alimera Sciences (NASDAQ: ALIM) have announced the closing date for their merger. The transaction is scheduled to close before the market opens on Monday, September 16, 2024. This announcement follows the previously disclosed Merger Agreement between the two companies. The merger represents a significant development in the pharmaceutical industry, potentially combining the strengths and resources of both entities.
ANI Pharmaceuticals (Nasdaq: ANIP) has provided an update on the status of its previously announced acquisition of Alimera Sciences (Nasdaq: ALIM). The company acknowledges Alimera's press release and states that it continues to work in good faith toward closing the acquisition. ANI attributes any delay to ongoing discussions regarding closing conditions, which it expects to resolve promptly. The update suggests that the acquisition process is still active, but certain details are being finalized before the transaction can be completed.